This week in therapeutics




Licensing status

Publication and contact information


Alzheimer's disease (AD)

Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2; LIR2)

Cell culture and mouse studies suggest blocking LILRB2 could help treat AD. In cultured cells, b-amyloid 42 (Ab42) oligomers bound selectively to LILRB2-expressing cells without binding to cells expressing related proteins. In hippocampal slices from mouse brains depleted of paired Ig-like receptor B (PirB), the homolog of LILRB2, Ab42 oligomers did not interfere with long-term potentiation. In a mouse model of AD, PirB knockout increased performance in learning and memory tests compared with no knockout. Next steps could include identifying LILRB2 antagonists.

SciBX 6(41); doi:10.1038/scibx.2013.1165
Published online Oct. 24, 2013

Patent pending; licensing status unavailable

Kim, T. et al. Science; published online Sept. 20, 2013;
Contact: Carla J. Shatz, Stanford University, Stanford, Calif.

Contact: Taeho Kim, same affiliation as above